Arbutus Biopharma Corp I9DN-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 03/28/24 CET
2.35quote price arrow up+0.09 (+3.74%)
52 week range
1.55 - 2.93
Loading...
  • Open2.36
  • Day High2.36
  • Day Low2.36
  • Prev Close2.35
  • 52 Week High2.93
  • 52 Week High Date03/30/23
  • 52 Week Low1.55
  • 52 Week Low Date10/24/23

Key Stats

  • Market Cap447.41M
  • Shares Out179.49M
  • 10 Day Average Volume2,005
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change3.97

KEY STATS

  • Open2.36
  • Day High2.36
  • Day Low2.36
  • Prev Close2.35
  • 52 Week High2.93
  • 52 Week High Date03/30/23
  • 52 Week Low1.55
  • 52 Week Low Date10/24/23
  • Market Cap447.41M
  • Shares Out179.49M
  • 10 Day Average Volume2,005
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change3.97

RATIOS/PROFITABILITY

  • EPS (TTM)-0.40
  • P/E (TTM)-5.89
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arbutus Biopharma Corp

 

Profile

MORE
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic...
Frank Torti M.D.
Independent Chairman of the Board
Michael Mcelhaugh
Interim President, Chief Executive Officer, Director
David Hastings
Chief Financial Officer
Elizabeth Howard J.D., Ph.D.
Executive Vice President, General Counsel, Chief Compliance Officer and Secretary
Address
701 Veterans Circle
Warminster, PA
18974
United States